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Summary
 
Junctional epidermolysis bullosa (JEB) is an autosomal recessive skin blistering disease with
both lethal and nonlethal forms, with most patients shown to have defects in laminin-5. We
analyzed the location of mutations, gene expression levels, and protein chain assembly of the
laminin-5 heterotrimer in six JEB patients to determine how the type of genetic lesion influ-
ences the pathophysiology of JEB. Mutations within laminin-5 genes were diversely located,
with the most severe forms of JEB correlating best with premature termination codons, rather
than mapping to any particular protein domain. In all six JEB patients, the laminin-5 assembly
intermediates we observed were as predicted by our previous work indicating that the 
 
a
 
3
 
b
 
3
 
g
 
2
heterotrimer assembles intracellularly via a 
 
b
 
3
 
g
 
2 heterodimer intermediate. Since assembly
precedes secretion, mutations that disrupt protein–protein interactions needed for assembly are
predicted to limit the secretion of laminin-5, and likely to interfere with function. However,
our data indicate that typically the most severe mutations diminish mRNA stability, and serve
as functional null alleles that block chain assembly by resulting in either a deficiency (in the
nonlethal mitis variety) or a complete absence (in lethal Herlitz-JEB) of one of the chains
needed for laminin-5 heterotrimer assembly.
 
E
 
pidermolysis bullosa (EB)
 
1
 
 is a family of genetic blister-
ing skin diseases with three major forms dependent
upon the exact layer of the skin where the split occurs (1,
2). In epidermolysis bullosa simplex defects in keratin 5 and
14 that make up tonofilaments within the basal kerati-
nocytes cause cell fragility and result in separation from the
suprabasilar layers (3, 4). In dystrophic forms of EB cleav-
age occurs just below the basement membrane zone due to
defects in anchoring filaments made of collagen VII (5, 6).
In the junctional forms of EB (JEB) blistering occurs at the
lamina lucida (1) and is associated with defects in the pro-
tein components of hemidesmosomes that attach basal ke-
ratinocytes to the basement membrane zone (BMZ). JEB is
an autosomal recessive disease, with six variants currently
recognized by the National Epidermolysis Registry (1),
ranging from the mild, localized JEB inversa form to the
severe, generalized JEB Herlitz form (H-JEB), which typi-
cally results in death early in infancy. In our study, we fo-
cused on the individual polypeptide chains of laminin-5,
the primary protein component of the anchoring filaments
shown to be most often defective in JEB. The anchoring
filaments connect the hemidesmosomes located along the
basal surface of basal keratinocytes to the underlying base-
ment membrane zone. Microscopy data have shown these
filaments to be absent or reduced in numbers in JEB (7, 8).
The first realization that laminin-5 is defective in JEB
came from immunofluorescence studies using the mono-
clonal antibody GB3, which illustrated reduced or absent
staining for the basement membrane of JEB patients (7, 9).
It was later shown that GB3 recognizes a large glycoprotein
(10) termed nicein (7), kalinin (11, 12), or epiligrin (13), by
different investigators, but is now known as the epithe-
lium-specific laminin variant, laminin-5 (14). Laminin-5 is
an isoform of the classical laminin, laminin-1(reviewed in
reference 15) and is also a heterotrimer that is presumed to
form a cruciform structure of disulfide linked chains (11).
 
1
 
Abbreviations used in this paper:
 
 1-D, 1-dimensional; BMZ, basement
membrane zone; EB, epidermolysis bullosa; JEB, junctional EB; PTC,
premature termination codon; SFM, serum-free media.
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There are three separate genes for the chains of laminin-5
(14), LAMA3 (16), LAMB3 (17), and LAMC2 (18, 19).
These code for three polypeptides (12): 
 
a
 
3
 
 
 
of 200 kD, 
 
b
 
3
of 145 kD, and
 
 
 
g
 
2 of 155 kD. The latter contains the anti-
genic determinant recognized by GB3 (20), the immu-
noreagent most often used in the diagnosis of JEB.
Extensive mutation detection analysis has been con-
ducted in numerous JEB patients for each of the laminin-5
chain genes and mutations have been mapped to each of
the chains, including 
 
g
 
2 (21–24), 
 
b
 
3 (25–27), and 
 
a
 
3 (28).
Such studies, designed to pinpoint the exact location of ge-
netic mutations in specific patients provide a potential
framework for correlations to be drawn between the site of
mutation and clinical phenotypes. For example, in JEB pa-
tients containing mutations in laminin-5 chains with the
most severe, lethal form of JEB (H-JEB) it was hoped that
there might be a clustering of mutations at certain locations
within the genes, reflecting protein domains most crucial to
laminin-5 function. Instead, the site of the genetic lesions
appears to vary widely.
We sought to further clarify how specific types of muta-
tions in laminin-5 chains result in the observed differences
in clinical phenotypes. An emphasis on understanding the
downstream effects of the mutations and comparing multi-
ple patient samples necessitated brevity in the presentation
of the mutation data. We biopsied JEB patients and cul-
tured keratinocytes because they provided us with the
unique opportunity of evaluating gene expression at both
the mRNA and protein levels. Here we analyze JEB pa-
tient keratinocytes with defects in each of the three chains
of the laminin-5 heterotrimer. The clearest correlation we
found was on the protein level, where the H-JEB patients
had a complete absence of any one of the three chains. In
contrast, the less severe mitis forms of JEB had normal, or
somewhat reduced, levels of one of the chains. The protein
analysis also provided a test for our hypothesis, described in
our previous studies, showing that the 
 
a
 
3
 
b
 
3
 
g
 
2 heterotri-
mer assembles intracellularly via a 
 
b
 
3
 
g
 
2 intermediate (29).
Since each of the H-JEB patients had one expressed chain
missing, the mutant genes for these chains performed as
functional null alleles, and allowed us to look at assembly
intermediates when each of the three chains was missing.
The assembly intermediates present in each of the H-JEB
patients were as predicted by our assembly model.
In general, the mRNA levels for the laminin-5 chains
corresponded to the observed protein levels, indicating that
the mutations are causing a net decrease in the mRNA lev-
els. Thus, mRNA levels for the mutant chains are often
drastically reduced, or undetectable in H-JEB patients as
compared with more normal levels in nonlethal JEB pa-
tients. These observations agree with both our data and
data from other laboratories that have shown that H-JEB
patients often have premature termination codons (PTCs)
in at least one allele (22, 30). PTCs have been shown to
give rise to unstable mRNA transcripts (31, 32), thereby
explaining the often undetectable mRNA levels. We con-
clude that it is the near, or complete absence of laminin-5
 
heterotrimer, typically caused by mutations that destabilize
one of the transcripts for laminin-5, that is the hallmark of
lethal H-JEB.
 
Materials and Methods
 
Patients.
 
Skin biopsies were obtained from six unrelated JEB
patients, D, G, J, L, M, and V (Table I). In all cases, JEB was di-
agnosed according to the revised criteria for subtyping EB (1).
Four patients (G, J, L, and M, all died shortly after birth) had the
severe Herlitz form of JEB, one patient had an intermediate form
of JEB (patient V alive at age 5), and the final patient had the
mild, generalized “mitis” form of JEB patient (patient D, died at
age 44). All patients had generalized blisters. mAb GB 3 did not
react with the skin biopsies from patients D, G, J, L, and M and
reacted only weakly with that of patient V. Transmission electron
microscopic analysis showed a dermal–epidermal split in the lam-
ina lucida and a reduced number of hemidesmosomes (data not
shown).
 
Cell Culture and Immortalization.
 
Keratinocytes were cultured
from neonatal foreskin for use as the normal control sample, and
from JEB patient skin biopsies. All gene expression experiments
were conducted using immortalized keratinocyte cell cultures,
because of the advantage of a more uniform and readily available
source of cells. Immortalized patient L keratinocytes were ob-
tained as described (33). Transfections of all of the other primary
cells were accomplished by lipofectin (GIBCO BRL, Gaithers-
burg, MD) after one or two passages. Cells were grown in serum-
free media (SFM; GIBCO BRL) and transfected with p18ccB
(34, 35), containing a subgenomic fragment of HPV-18 encoding
intact open-reading frames of E6 and E7. These genes are suffi-
cient for inducing the immortalization of keratinocytes. At 2 d af-
ter transfection, selection by G418 (100 mg/ml; Sigma Chemical
Co., St. Louis, MO) was applied for a total of 3–4 d. Individual
colonies were cloned and passaged once a week at a split ratio of
1:6 or 1:8. The cell lines that survived 
 
.
 
20 passages in culture
were considered immortalized and used for study.
 
Antibodies.
 
Polyclonal anti–laminin-5 antisera (11) was kindly
provided by Dr. Peter Marinkovich (Stanford University, Stan-
ford, CA). Polyclonal anti-
 
b
 
3 antisera was raised against a glu-
tathione/S-transferase/laminin-5 
 
b
 
3
 
 
 
fusion protein as previously
described (29).
 
Biosynthetic Labeling and Immunoprecipitation.
 
Immortalized ke-
ratinocytes  from both normal and JEB patients were cultured in
SFM. Dissociated cells were seeded at 10
 
5
 
 cells per 60-mm dish,
allowed to attach in complete growth medium for 24 h, and then
incubated in methionine- and cysteine-deficient SFM for 2 h. Cells
were then cultured in deficient SFM containing 50 mCi/ml of
protein labeling mix ([
 
35
 
S]methionine and [
 
35
 
S]cysteine; Dupont-
NEN, Boston, MA) for 24 h. Cell and medium fractions were
processed for immunoprecipitation, which was performed as pre-
viously described (20). In brief, cell layers were harvested with a
cell scraper and ice-cold RIPA buffer (10 mM Tris-HCl, pH 7.4,
150 mM NaCl, 2 mM EDTA, 250 mM PMSF, 1 mM 
 
n
 
-methyl-
maleimide, 2 mM 
 
L
 
-methionine, 2 mM 
 
L
 
-cysteine, 0.3% NP-40,
0.05% triton X-100, 0.3% sodium deoxycholate, and 0.1% BSA
containing 0.1% SDS). 250 mM PMSF was added to the culture
medium which was then centrifuged at 12,000 rpm to remove
cells and debris. TCA-precipitable radioactivity of the medium
and cell fractions was counted. Both the medium (2.0 
 
3
 
 10
 
6
 
TCA-precipitable cpm) and the cell lysate (2.0 
 
3
 
 10
 
7
 
 TCA-pre-
cipitable cpm) were cleared by the addition of preimmunized 
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rabbit serum, anti-rabbit IgG-conjugated agarose beads (Sigma
Chemical Co.), and gelatin sepharose (Pharmacia Biotechnology,
Inc., Piscataway, NJ) for 1 h at 4
 
8
 
C. Immunologically reactive
laminin-5 was precipitated from precleared medium and cell frac-
tion by 16 h incubation with a mixture of anti-rabbit IgG-conju-
gated agarose beads and anti–laminin-5 antisera. After incubation,
precipitates were pelleted by centrifugation at 2,500 rpm for 10
min and washed with RIPA buffer (medium sample) or RIPA
buffer containing 0.1% SDS (for cell extract). After five washes,
the pellets were mixed with SDS sample buffer, heated to 95
 
°
 
C
for 3 min and analyzed by SDS-PAGE.
 
Gel Electrophoresis.
 
Two-dimensional SDS-PAGE was per-
formed as previously described (36). After soaking the gels in
Amplify (Amersham Pharmacia Biotechnology, Buckingham-
shire, England), fluorography was used to visualize radiolabeled
proteins in the acrylamide gels followed by drying and exposure
to film.
 
Northern Blot Analysis.
 
Total RNA was prepared from patient
and normal cells using RNAeasy (QIAGEN Inc., Chatsworth,
CA). The RNA was subjected to electrophoresis on a 1.2% dena-
turing agarose gel containing 1.2 M formaldehyde and transferred
onto nylon membranes (Hybond N; Amersham Pharmacia Bio-
technology). Membranes were subsequently hybridized at high
stringency with 
 
32
 
P-labeled cDNA probes for the laminin-5
chains as follows; Na3 for the 
 
a
 
3 chain (37), PCR1.3 for the 
 
g
 
2
chain (19), and kal 85 for the 
 
b
 
3 chain (17), using RapidHyb
(Amersham Pharmacia Biotechnology). Blots were exposed to x-ray
film using intensifying screens.
 
DNA Isolation and PCR Amplification.
 
Genomic DNA was
isolated from peripheral blood lymphocytes by standard proce-
dures and used as a template for amplification of individual exons
within the LAMB3 gene. Oligonucleotide primers spanning each
of the gene’s 23 exons were synthesized on the basis of intronic
sequences to generate PCR products. For amplification by the
PCR, 
 
z
 
50 ng of genomic DNA was used as the template in a re-
action mixture containing 5 
 
m
 
l of Gene Amp 10
 
3
 
 PCR buffer
with MgCl
 
2
 
 (Perkin-Elmer Corp., Norwalk, CT), 2.5 mM of
each nucleotide, 10 pmol of each primer and 1.25 U of Ampli-
Taq DNA Polymerase (Perkin-Elmer Corp.) in a total volume of
50 
 
m
 
l. The PCR primers used to identify only those mutations
shown here are listed below with 5
 
9
 
 identifying numbers and us-
ing R to indicate sense strand and L to indicate antisense: patient
J in exon 3, 
 
2
 
130 R gcagcgagtggaagcttg, 
 
1
 
130 L gtataaggcca-
gatcctagcc; patient V in exon 7, 
 
2
 
98 R ttcaagtgtgaggcatataatgg,
 
1
 
133 L gatttgatacttgccctgcttg; patient M in exon 15, 
 
2
 
183 R
gattgtgctggtcgccaagcc, 
 
1
 
202 L tcgcgccttttggaccagct; patient M in
exon 20, 
 
2
 
158 R ggggtcctgggacatcaaagctac, 
 
1
 
341 L gttcagcagg-
tactgcggcc; and patient D in exon 17, 
 
2
 
64 R cgtgtggggtggattggt-
tatt, 
 
1
 
105 L acactaaagtccagagattttaggtga.
The primers correspond to flanking intronic sequences. In the
case of sense primers, the number indicates the position upstream
from the intron–exon border and in the case of antisense primers,
to the position downstream from the exon–intron border. The
amplification conditions for the typical primer were 94
 
8
 
C for 7
min followed by 40 cycles of 94
 
8
 
C for 45 s; 50–66
 
8
 
C for 45 s;
72
 
8
 
C for 1 min in a 9600 GeneAmp PCR thermocycler (Perkin-
Elmer Corp.). 5-
 
m
 
l aliquots of the PCR products were analyzed
on a 3% agarose gel and visualized by ethidium bromide staining.
 
Heteroduplex Analysis.
 
10 
 
m
 
l of the PCR sample was prepared
for heteroduplex analysis according to the Mutation Detection
 
Table 1.
 
Clinical Phenotype and Location of Mutations in JEB Patients
 
Patient G D V J M L
Diagnosis H-JEB JEB mitis JEB mitis H-JEB H-JEB H-JEB
Age & status Dead at 9 wk Dead at 44 yr Alive at 7 yr Dead at 8 wk Dead at 1 yr Dead at 8 wk
Defective chain
 
a
 
3
 
b
 
3
 
b
 
3
 
b
 
3
 
b
 
3
 
g
 
2
Type of mutation ND PTC Splice site PTC PTC PTC
Location (cDNA) ND C2621T G754A C250T 3112delC C283T
A.A. location ND Q832X E210K R42X V1027X R95X
Protein domain ND Dom-I/II Dom-VI Dom-VI Dom-I Dom-V
Type of mutation ND ND ND PTC PTC
Location (cDNA) ND ND ND C250T G2257(
 
1
 
)T
 
*
 
C283T
A.A. location ND ND ND R42X (In intron) R95X
Protein domain ND ND ND Dom-VI Dom-II Dom-V
Comparison of clinical data from six JEB patients shows two distinct groups, one group with lethal H-JEB (patients G, M, J, and L, all died within
the first year), and the other group with less severe JEB mitis (patient D died as an adult and patient V is alive at age 7). Defects were detected in each
one of the three laminin-5 chains, 
 
a
 
3, 
 
b
 
3, or 
 
g
 
2. Genetic information for patients M
 
1
 
 and L (22) were from a previous analysis, and include both al-
leles. Identification of single allele mutations for patients D and V are presented in Fig. 2, 
 
A
 
 and 
 
B
 
. Patient J contained a homozygous PTC and is
presented in Fig. 2 
 
C
 
. PTC, premature termination codon, location in cDNA indicates nucleotide normally at the position, followed by the num-
bered nucleotide position (numbering from the first nucleotide of the transcript including a 128-bp leader preceding the AUG), and ended by the
nucleotide substitution. 
 
*
 
 Indicates mutation located one base past nucleotide position 2257 as indicated by 
 
1
 
 in the first base of intronic splice con-
sensus sequence. A.A., amino acid location indicates amino acid normally at the position, followed by the numbered A.A. position, and ended by the
amino acid substituted, or stop codon, at that position. 
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Enhancement (MDE) protocol supplied by the manufacturers (JT
Baker Inc. Phillipsburg, NJ). Samples were run both using PCR
products amplified from patient DNA alone, or were mixed with
PCR products amplified from normal DNA, to detect heterodu-
plexes. Staining with ethidium bromide was used to visualize the
heteroduplexes (data not shown)
 
.
Genomic DNA Sequencing.
 
When a heteroduplex was detected,
the PCR product was sequenced by cycle sequencing (Sequi-
therm cycle sequencing; Epicentre Technologies Corp., Madi-
son, WI) and run on a 6% denaturing polyacrylamide gel using
the Genomyx LR system (Genomyx, Foster City, CA). Muta-
tions were confirmed by separate rounds of PCR amplification
followed by cycle sequencing, repeated at least three times to di-
minish the possibility of PCR generated mutations. Mutations
from three previously uncharacterized JEB patients are presented
here, patients D, J, and V. Family members were not readily
available for patients D or V, so no familial analysis or verification
was performed. Patient J’s mutations were confirmed by familial
analysis (data not shown).
 
Results
 
Clinical Phenotypes and Location of Mutations in Junctional
Epidermolysis Bullosa Patients.
 
Six unrelated JEB patients
were selected for investigation in this study (Table I), in-
cluding four patients with the H-JEB and two patients with
the less severe mitis variety. These six patients were chosen
for presentation because defects in each of the three lami-
nin-5 chains of the heterotrimer are represented. Specifi-
cally, we sought to evaluate the effect on laminin-5 chain
assembly when each of the three chains of the heterotrimer
is defective. Because the highest percentage of JEB patients
contain mutations in the 
 
b
 
3 chain (30), we also present
four patients with mutations in the 
 
b
 
3 chain (patients D, V,
J, and M). These patients demonstrate a correlation be-
tween the type of mutation, its effect on laminin-5 expres-
sion, and the severity of the clinical phenotype.
Two patients with b3 chain mutations had the less se-
vere mitis form of JEB (patient D and V), and a single allele
mutation for each patient is presented. The mutation iden-
tified in patient D is a PTC resulting from a nonsense mu-
tation. In patient V we identified a splice site mutation.
Two patients (J and M) with H-JEB who had b3 chain
mutations were also characterized. Patient J is homozygous
for a nonsense mutation at a position located early in the
transcript for the b3 chain. The location corresponds to a
mutational hotspot previously identified (30) but character-
ized for the first time here in this patient. Patient M has a
single-bp deletion on one allele that creates a frame shift re-
sulting in a PTC 94 bp downstream, and a splice site muta-
tion on the second allele (35). We also present patient G
with a defect in the a3 chain as judged by protein and
mRNA data, but for whom the exact location of mutation
has not yet been determined. Finally, patient L with a g2
chain defect is presented containing a homozygous non-
sense mutation that has been previously identified (22). By
collecting protein assembly data for patient L, we further
clarify the impact of these g2 chain mutations.
The locations of laminin-5 mutations in these patients
are summarized in Fig. 1. The diverse locations of these
mutations exemplifies the lack of correlation between clin-
ical severity and localization of mutations to specific do-
mains. Some of the mutations in these patients were local-
ized to the NH2-terminal ends of the chains that form the
short arms of laminin-5, as indicated for patients L, J, and
V. Other mutations were contained within the COOH-
terminal domains I/II that form the long arm, shown for
patients D and M. This region is presumed to form a triple
a-helical coiled-coil (14, 38) based on homology to lami-
nin-1, and is important for the assembly of the three chains
into a heterotrimer.
Identification of Mutations in Laminin-5 Chain Genes. Two
of the patients studied have previously published mutations
(patient L [22] and our earlier work on patient M [Pereira,
P., C. Tzou, L. Pan, T. Kutzkey, K. Hultquist, S. Cobberly,
L. Nall, J. McGuire, M.P. Marinkovich, E.A. Bauer, G.S.
Herron, W.K. Hoeffler, and E.A. Welsh, manuscript sub-
mitted for publication]), whereas three of the other patients
were previously uncharacterized for their mutations in the
b3 chain (patients D, V, and J). We show direct DNA se-
quencing of PCR products amplified from genomic DNA
Figure 1. Structural model of laminin-5 and location of analyzed muta-
tions. Protein domains in the a3, b3, and g2 chains are labeled with ro-
man numerals by homology to laminin-1. The short arms contain globu-
lar domains flanked by EGF-like repeats as depicted by the small circles.
The long arms of the three chains are associated in an a-helical coiled-
coil of approximately the same length as in laminin-1, 600 AA. The hep-
tad repeats of the long arm are interrupted at one region in the b3 chain,
termed the A region. The a3 chain contains a COOH-terminal end with
a globular extension containing five similar regions (G domain). Arrows
with single letter designations denote approximate locations of mutations
for the JEB patients discussed.1277 Matsui et al.
from these three patients. To screen for mutations, a series
of PCR products spanning the entire LAMB3 gene were
resolved on MDE gels to distinguish heteroduplex mis-
matched DNA strands indicative of polymorphic sequence
variations (data not shown). Direct DNA sequencing of a
polymorphic PCR product using primers spanning exon
17 for patient D revealed a C-to-T transition at position
2621 of the cDNA (Fig. 2 A). A comparison of the normal
sequence on the right with that of the proband on the left
shows that the C position signal drops to 50% intensity at
this position and that a T also appears at this same position.
A nonsense mutation is created on one of the alleles where
the T appears but is normal at this position in the other allele.
Direct DNA sequencing of a polymorphic PCR product
using primers spanning exon 7 of patient V revealed a G-to-A
transition at position 754 of the cDNA. A comparison of
the normal sequence on the right with that of the proband
on the left shows the presence of an A only in the proband
(Fig. 2 B, arrow), as well as a lighter band in the G lane for
the same position. Both the G and A bands are visible be-
cause both alleles of the b3 chain gene (normal and mu-
tant) are equally represented in the PCR product. The
transition of a G-to-A occurs within the consensus splice
donor site AG/GT. Although, this is the first characteriza-
tion of a mutation in this patient, interestingly the same lo-
cation of mutations was reported previously for two other
unrelated, nonlethal JEB patients (25, 39).
Patient J was analyzed by direct DNA sequencing of a
polymorphic PCR product using primers spanning exon 3,
and revealed a C-to-T transition at nucleotide position 250
of the cDNA. The normal sequence on the right shows the
presence of a C on both alleles at this position, in agree-
ment with the published sequence for the b3 chain (Fig. 2
C, arrow in left panel). The same position in patient J con-
tains only a T. Because both alleles of the b3 chain gene are
equally represented in the PCR product, patient J is ho-
mozygous for a T at position 250. This point mutation re-
sults in the change of an arginine (CGA) to a PTC (TGA),
represented as R42X. Although this is the first characteriza-
tion of this particular patient, the location of this mutation
was previously identified in other patients as a mutational
hotspot (30). The repeat findings of mutations in additional
unrelated patients will eventually facilitate screening proce-
dures, since mutational hotspots can be probed for directly.
Considering our current emphasis on understanding the
downstream effects of underlying mutations by characteriz-
Figure 2. DNA sequencing of mutations in JEB patients. (A) Direct
DNA sequencing of patient D’s PCR amplified genomic DNA revealed a
heterozygous C-to-T transition (arrow) at position 2621 of the cDNA re-
sulting in a stop codon substituted for a glutamine residue designated as
Q832X. Shown is the sense strand reading 59 to 39 from bottom to top.
Both the cytosine normally present and the substituted thymine are visible
at the location. An unrelated normal is analyzed in the right panel and
shows only a cytosine at this position. (B) Direct DNA sequencing of pa-
tient V’s PCR amplified genomic DNA showed a heterozygous G-to-A
transition (arrow) at position 754 of the cDNA resulting in a splice site
mutation at the exon 7, intron 7 junction. Shown is the sense strand read-
ing 59 to 39 from bottom to top. Both the guanine normally present and
the substituted adenine are visible at this location. An unrelated normal is
analyzed in the right panel and shows only a guanine at this position. (C)
Direct DNA sequencing of patient J’s PCR amplified genomic DNA
showed a homozygous C-to-T transition (arrow) at position 250 of the
cDNA resulting in a nonsense mutation in exon 3, designated R42X. An
unrelated normal is analyzed in the right panel and shows only a guanine
at this position.1278 Laminin-5 Assembly Defects in Junctional Epidermolysis Bullosa
ing mRNA levels and determining effects on laminin-5
chain assembly, the more common mutations are preferred
examples since they are representative of more patients.
Northern Analysis of mRNA Levels of All Three Laminin-5
Chains in JEB Patients. Total RNA was isolated from ke-
ratinocyte cultures from either normal or JEB patients.
Transcripts of the expected size were observed for each of
the laminin-5 chains using normal keratinocyte RNA (Fig.
3, lanes N on both sides). Patient G, who does not produce
a3 chain protein, gave no detectable signal for a3 mRNA.
However, mRNA was detectable for both the b3 and g2
chains, although at somewhat reduced levels compared
with normal (lane G). Patient M, who we previously char-
acterized as containing mutations in the b3 chain did not
produce detectable mRNA for the b3 chain, whereas a3
mRNA was produced at a reduced level, and g2 was pro-
duced at normal, or perhaps greater levels (lane M). The
other previously characterized JEB patient, patient L, had
no detectable mRNA for the g2 chain, but did produce
mRNA for the a3 and b3 chains. Three of the four JEB
patients containing b3 chain mutations produced detect-
able levels of all three chains. Patient D produced normal
levels of all three chains, whereas patient V had reduced
levels of b3 chain mRNA, and somewhat reduced levels of
a3 chain mRNA as well. Patient J, with homozygous PTC
mutations in the b3 chain, had detectable, but somewhat
reduced, levels of the b3 transcript. The levels for the
mRNAs of the a3 and g2 chains were normal. The pres-
ence of mRNA for the b3 chain is noteworthy because
other patients with PTC mutations often showed no de-
tectable mRNA for the chain containing the mutation
(compare to patients M and L).
Laminin-5 Subunit Assembly in Patient Keratinocytes. Lami-
nin-5 immunoprecipitates from normal and patient kerati-
nocytes were examined by two-dimensional (2-D) SDS-
PAGE. In the normal cell lysate the 460-kD complex (Fig.
4 A, top panel, abg) observed under nonreducing condi-
tions dissociated under reducing conditions into an equimolar
mixture of a3, b3, and g2 subunits (larger panel, three spots
directly below band, solid triangle). The second specific
band (s) from the origin dissociates under nonreducing
conditions into two protein bands of 145 and 155-kD, in-
dicative of the disulfide-linked b3g2 heterodimer we iden-
tified previously (Fig. 4 A, larger panel, two spots directly be-
low band, open triangle; reference 29). Monomers of the three
subunits, run under reducing conditions, are shown as mark-
ers in the right side panels (Fig. 4, A–E) and appear as spots
along a diagonal (larger panels).
In the culture medium (Fig. 4 A, right-hand panels) the
two forms of extracellularly processed laminin-5, 440-kD
(a9bg) and 400-kD (a9bg9) were observed under nonre-
ducing conditions. Under reducing conditions the 440-kD
form (right-most band in top panel) dissociated into a mix-
ture of processed 165-kD a3 and 140-kD b3, and unpro-
cessed 155-kD g2 subunits. The 400-kD laminin-5 (the
second band from the origin under nonreducing condi-
tions) also dissociated into processed a3 and b3, but dis-
played a complete substitution of the processed 105-kD g2
chain for unprocessed 155-kD g2 (larger panel, two sets of
three spots directly below each of two bands, solid triangle).
To simplify discussions only the main larger panels contain-
ing the 2-D gels for each figure are referred to in the fol-
lowing descriptions, and not the side panels containing 1-D
gels.
In the cell lysate from patient G (Fig. 4 B), the largest
complex observed under nonreducing conditions is het-
erodimeric b-g (Fig. 4 B, bottom left panel two spots above
open triangle). Monomers of b3 and g2 subunits were also
present, but because the a3 subunit was completely absent,
no heterotrimer assembly involving this subunit was found
(no spots visible above solid triangle). Likewise, in the me-
dium from patient G (Fig. 4 B, bottom right panel) the ab-
sence of assembly resulted in the near absence of secreted
forms (no spots visible above solid triangle). Only g2 chain
monomers were observed; other subunits were not detect-
able even after longer exposure of the gel (data not shown).
The following three JEB patients showed defects in the
b3 chain but display unique characteristics (Fig. 4, C–E).
The assembly pattern of laminin-5 is essentially normal for
patient D, except that a truncated form of b3 (bt estimated
120-kD molecular mass) substitutes for the normal b3
chain. Thus, in the cell lysate from patient D (Fig. 4 C), all
three chains of the heterotrimer assemble (top left panel,
three spots above solid triangle). The heterodimer also
Figure 3. H-JEB patients’ mRNA levels for the mutant chains are gen-
erally lower than in nonlethal JEB. Northern analysis of total RNA iso-
lated from keratinocytes from either an unrelated normal control (N, lanes
1 and 8), lethal H-JEB (patients G, M, and L, lanes 2–4, and J, lane 7), or
nonlethal JEB (patients D, V, lanes 5 and 6) hybridized with probes spe-
cific for laminin-5 chains, a3 (top panel), b3 (middle panel), g2 (bottom
panel), and for GAPDH as a control for approximately equal loadings of
RNA. Film exposure for the a3 chain on patients V,G, and L was fivefold
longer than for the other lanes because of a lower a3 signal in these pa-
tients. Position of RNA size markers shown on the right. Northern for
patient J was done separately, lane 7, and is compared with a normal con-
trol, lane 8.1279 Matsui et al.
forms normally (two spots above open triangle). These data
show that the truncated b3 protein from patient D is capa-
ble of heterodimer and heterotrimer formation. The me-
dium from patient D (Fig. 4 C, top right panel) again shows
the normal pattern of assembled heterotrimer (three spots
above solid triangle), but incorporates the truncated b3
chain. Interestingly, monomeric a3 and g2 chains were
also present and migrated to a central position along the di-
agonal in the 2-D gels, with degradation products of these
monomers seen along the diagonal on the lower left. The
larger molecular mass band of fibronectin is also seen, al-
though none of the detectable forms appear to be associ-
ated with the laminin-5 complexes.
A somewhat greater deviation from the normal pattern
was observed in the cell lysate from patient V (Fig. 4 D).
Although the heterotrimer was detectable, the amount was
more than fivefold less than in normal cells (the autoradio-
graph was exposed five times longer than for the normal
keratinocyte sample). No heterodimer formation was visi-
ble under reducing conditions (no doublet spot seen above
open triangle). Instead, multiple high molecular mass bands
(gn) were present which lined up entirely with the 155-kD
g2 chain upon reduction. Disulfide-linked multimers (spots
directly below gn bands) of the g2 subunit are present. We
previously reported multimer formation of recombinant g2
subunits (29). Monomers of the a3 and g2 subunits are
present, whereas the b3 monomer is absent. The severely
reduced level of b3 subunit appears to be the limiting sub-
unit for heterotrimer assembly in this patient. Likewise, in
the medium from patient V (Fig. 4 D, bottom right panel) less
assembly resulted in lower levels of secreted heterotrimer
(three spots visible above solid triangle). Monomeric a3
and g2 chains were also present and migrated to a central
position along the diagonal of this 2-D gel. The larger band
of fibronectin is also seen, and appears to be associated with
the g2 chain.
Figure 4. Assembly of laminin-5 chains in JEB patient keratinocytes.
Cells were radiolabeled for either 2 h (lysates-derived from whole cells) or
24 h (medium-secreted proteins in tissue culture) and immunoprecipi-
tated with anti–laminin-5 antiserum. The samples were subjected to 2-D
SDS-PAGE as described in Materials and Methods. Electrophoresis in the
first dimension was performed under nonreducing conditions, and in the
second dimension under reducing conditions. Duplicate nonreducing (top
panels) and reducing (side panels) gels are shown along each dimension to
allow alignment of the component chains seen in the 2-D gel. Open tri-
angle points to position of b3g2 heterodimers, when present. Solid trian-
gle points to position of a3b3g2 heterotrimers. Gels show the result
when each of the three laminin-5 chains is missing due to mutation in a
particular JEB patient. (A) Normal keratinocyte lysate (left panel) and tis-
sue culture medium (right panel), all chains present. (B) Patient G kerati-
nocyte lysate (left panel) and tissue culture medium (right panel), a3 chain
missing. (C) Patient D keratinocyte lysate (left panel) and tissue culture
medium (right panel), truncated b3 chain. (D) Patient V keratinocyte ly-
sate (left panel) and tissue culture medium (right panel), b3 chain defi-
ciency. (E) Patient M keratinocyte lysate (left panel) and tissue culture me-
dium (right panel), b3 chain missing. (F) Patient L keratinocyte lysate (left
panel) and tissue culture medium (right panel), g2 chain missing. (a) un-
processed a3 subunit; (b) b3 subunit, (bt) truncated b3 subunit; (g) un-
processed g2 subunit; (a9) processed a3 subunit; (g9) processed g2 sub-
unit; (FN) fibronectin.1280 Laminin-5 Assembly Defects in Junctional Epidermolysis Bullosa
The cell lysate from patient M displays a complete lack
of b3 chain expression and the consequent absence of
larger complexes (Fig. 4 E, top left panel, no spots above
solid triangle). Some multimerization of the g2 chain is vis-
ible, whereas no bg heterodimer forms (no spots above
open triangle). In the medium from patient M (Fig. 4 E,
top right panel) the lack of assembly resulted in the absence
of secreted forms (no spots above solid triangle), although
some g2 chain is present. Likewise, patient J has a complete
absence of b3 chain expression as analyzed on Western
blots (data not shown), and we conclude patient J has an
analogous pattern of expression to patient M.
A similar situation is observed in the cell lysate from pa-
tient L (Fig. 4 F). Again, there is an absence of larger com-
plexes (no spots above open or solid triangles) resulting
from the lack of g2 chain. Only a3 and b3 monomers are
present. Similarly, in the medium from patient L (Fig. 4 F,
bottom right panel) the lack of assembly resulted in the ab-
sence of secreted forms (no spots above solid triangle).
Discussion
We present information on the synthesis of mutant gene
products in junctional epidermolysis bullosa patients with
laminin-5 defects, coupled with mutation site mapping
data, to provide insight into ways that genetic lesions effect
gene product function. We found that clinical severity cor-
responded to the extent of laminin-5 heterotrimer assem-
bly. The hallmark of the most severe form of JEB, H-JEB,
is the lack of one of the protein chains needed to assemble
laminin-5, causing an absence of the heterotrimer, as
shown here for patients G, M, J, and L. The lack of expres-
sion could often be traced to the near absence of RNA
transcripts (Fig. 3) in the patients we analyzed, several of
whom had PTCs. Others have shown that PTCs can cause
instability of the RNA (31, 32, 40), and the importance of
this mechanism in creating the downstream effects of many
human genetic diseases needs to be more fully recognized.
The H-JEB patients presented have functional null alleles
for one of the laminin-5 chains. In contrast, we found that
in the nonlethal generalized atrophic benign, or mitis vari-
eties, expression of the mutant chains’ mRNA (Fig. 3) and
protein (Fig. 4, A–F) were reduced, but not absent, as
shown here for patients D and V.
Laminin-5 is a primary component of anchoring fila-
ments, which through their association with hemidesmo-
somes, are responsible for attachment of basal epithelial
cells to the BMZ. Four of the six patients had H-JEB, and
were chosen for presentation because each was defective in
one of the three chains of the heterotrimer, the a3 chain
(patient G), the b3 chain (patients M and J), and the g2
chain (patient L). We analyzed these patients for synthesis
and secretion of the individual chains of the laminin-5 het-
erotrimer by immunoprecipitation and resolution on 2-D
gels. The same methodology was used in our earlier study
on laminin-5 chain assembly conducted in SCC25 cells
(29). This allowed us to determine both the amounts of the
component chains expressed, and the extent of assembly of
chain monomers into larger complexes. We concluded ear-
lier that the assembly of laminin-5 proceeds from a b3g2
heterodimer to the a3b3g2 heterotrimer. These observa-
tions provided the basis for our interpretation of any devia-
tions from normal laminin-5 assembly found in JEB pa-
tients. In normal keratinocytes (Fig. 4 A) both the b3g2
heterodimer (spots above open triangle) and the a3b3g2
heterotrimer (spots above solid triangle) are seen in the ly-
sate (left panel), whereas in the medium (right panel) only the
heterotrimer is secreted (spots above solid triangle). For pa-
tient G with H-JEB (Fig. 4 B) there was an absence of de-
tectable a3 chain, but the b3g2 heterodimer was still evi-
dent as an assembly intermediate (spots above open triangle).
This observation is consistent with our earlier finding of
b3g2 heterodimer formation in the absence of the a3
chain (29). The heterodimer was not secreted into the cul-
ture medium, although some g2 chain monomeric com-
plexes were secreted in the absence of complete heterotri-
mer assembly. In patient D with nonlethal JEB (Fig. 4 C) the
b3 chain was truncated (bt), but was still able to associate
normally into heterodimers and heterotrimers (spots above
open and solid triangles). This is the first description of a
JEB patient with normal levels of mRNA for all three
chains, and a nearly normal pattern of assembly of the indi-
vidual chains into laminin-5. Patient V with nonlethal JEB
(Fig. 4 D) produced limiting amounts of b3, so that no b3
was found as monomers or heterodimers but all was incor-
porated into heterotrimers (spots above solid triangle). In
contrast, in patient M with H-JEB (Fig. 4 E) a frame shift
PTC abrogated production of the b3 chain resulting in an
absence of b3g2 heterodimer (no heterodimer spot above
open triangle) and a complete absence of heterotrimers (no
spots above solid triangles). Another H-JEB patient, patient
J, also had a complete absence of b3 protein (data not
shown) due to the presence of homozygous PTCs posi-
tioned early in the transcripts. Similarly, H-JEB patient L
(Fig. 4 F) shows a complete absence of the g2 chain, result-
ing in no heterodimer or heterotrimer formation (no spots
above either open or solid triangle). This illustrates again
that H-JEB patients have a total absence of one of the
chains of laminin-5, and therefore possess a functional null
allele phenotype.
Complete assembly does not occur in the absence of any
one of the chains of the heterotrimer, and therefore no sig-
nificant amount of laminin-5 is secreted. We found that the
g2 chain could multimerize in the absence of one of the
other chains, and was secreted to a limited extent. H-JEB
keratinocytes provided natural ‘knockout’ genes for lami-
nin-5 chains and were thus valuable reagents for under-
standing assembly, helping to confirm our earlier findings
of an ordered assembly from a b3g2 heterodimer to the
heterotrimer (29). Our results also explain why chain spe-
cific antibodies have not been particularly informative in
discerning which chain contains the gene mutation (41),
since defects in any of the three chains can limit assembly
and secretion of the complete heterotrimer. In the patients1281 Matsui et al.
shown here a null allele phenotype for any of the chains
correlated with lethal H-JEB, whereas nonlethal JEB pa-
tients exhibited some expression of the mutant alleles.
The variable levels of functional laminin-5 chains seen in
JEB patients is a reflection of both the type and location of
mutation. By bringing together data identifying mutations
and characterizing laminin-5 expression, we can improve
our ability to predict how certain mutations will effect ex-
pression. The predictive power of mutational data for
guessing clinical phenotypes will improve if we can discern
the set of rules governing final expression levels from mu-
tant alleles. An earlier effort to characterize expression lev-
els in JEB patients was conducted before mutation data was
readily available, so no correlations between expression
levels and mutant alleles were drawn. That study also fo-
cused only on H-JEB patients, and did not include an anal-
ysis of less severely effected JEB patients (42). In addition to
establishing the correlation between the extent of laminin-5
expression and the severity of JEB, we also show that the
laminin-5 protein levels are reflected in the mRNA levels.
Thus, the absence of laminin-5 protein can often be traced
to the absence of mRNA transcript (Fig. 3). The prepon-
derance of PTC mutations among H-JEB patients is noted
in our data (Table I) and in published work that first identi-
fied the hotspot mutation R42X (30), that we also found to
be present in our patient J. We show for the first time in
H-JEB that the presence of PTCs typically cause a dramatic
reduction in the mRNA levels from the mutant alleles. A
smaller decrease in mRNA from a patient with the milder
generalized atrophic benign form of JEB containing a PTC
has been previously noted (25). Others have pointed out
the high probability of PTCs being present in H-JEB pa-
tients (43). Our work is independent confirmation of this
observation, and importantly, we add protein data and
RNA analysis to show the functional significance of the
PTCs. In other systems PTCs have been shown to destabi-
lize mRNA transcripts (31, 32). Our data may also suggest
a functional difference in the ability of different types of
PTCs to trigger so-called ‘nonsense mediated mRNA de-
cay’(38, 44). Patient M keratinocytes have a PTC that re-
sults from a frameshift located downstream of a deletion,
and the mRNA levels for that transcript are dramatically
reduced. In contrast, patient J with homozygous nonsense
PTCs has less of a reduction in message levels, and there-
fore the effect of all PTCs may not be equivalent in terms
of mRNA stability. Perhaps if the location of the PTC in
patient J were further downstream a stable truncated prod-
uct could be produced, since clearly the mRNA transcript
is present. Patient D may illustrate this phenomenon, since
no reduction in mRNA level is seen for the mutant tran-
script, despite the presence of a nonsense PTC on one al-
lele in this patient. Patient L may be an exception, where
nonsense PTCs resulted in undetectable mRNA levels of
the mutant transcripts (but in this case the cells were ob-
tained from a different laboratory and were immortalized
using a different protocol). Also in agreement with our ob-
servations is previously published data on a JEB patient
with a nonsense PTC where only a small reduction in the
mutant transcript was noted. However, the significance of
the slight reduction in mRNA levels as being characteristic
of less severe disease had not been noted (25). Our data
from patient J also points out that H-JEB may afflict pa-
tients with less significant reductions in mRNA levels if
both alleles contain nonsense mutations early in the tran-
script that result in a total absence of translated protein. The
current understanding among EB researchers is that all
PTCs within laminin-5 have identical consequences. How-
ever, we believe that there may be possible differences in
mRNA stability between nonsense PTCs and frameshift
PTCs that could result in clinical differences. Experiments
further addressing these observations are currently ongoing
in our laboratory.
The molecular characterization of JEB patients is an im-
portant step toward future targeting of this disease for gene
therapy. There are two possible methods of introduction of
the therapeutic gene. The first is simply the addition of the
therapeutic gene in the patient host cells that still contains
the defective version. The second involves the removal of
the defective copy of the gene and replacement with a nor-
mal copy through homologous recombination. The at-
tempts at conducting gene therapy using the first method
require a determination of the extent to which the endoge-
nous defective gene products may interfere with the func-
tion of the therapeutic gene in the patient host cells. Many
genetic diseases, including JEB, are recessive and therefore
the assumption is that the addition of a normal gene copy
will be dominant and restore function. Yet considerations,
such as relative levels of expression of the therapeutic gene
versus endogenous gene, may complicate the results. Fur-
thermore, it remains possible that not all patient back-
grounds will respond equivalently to gene therapy efforts.
In some JEB patients the transcripts from the mutant alleles
are unstable, as in patients M, L, and G, whereas in others
they are more stable, as in patient J, and perhaps patients D
and V. From our results, it is not clear whether the thera-
peutic gene transcript would be equally stable in these two
categories of patient host cells. Further work is required to
determine how various patient backgrounds respond to the
addition of a therapeutic gene.
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